These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 27581212)
1. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells. Shen Q; Qiu L J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212 [TBL] [Abstract][Full Text] [Related]
2. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition. Gao M; Xu Y; Qiu L J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110 [TBL] [Abstract][Full Text] [Related]
3. Doxorubicin and chloroquine coencapsulated liposomes: preparation and improved cytotoxicity on human breast cancer cells. Qiu L; Yao M; Gao M; Zhao Q J Liposome Res; 2012 Sep; 22(3):245-53. PubMed ID: 22607110 [TBL] [Abstract][Full Text] [Related]
4. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance. Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761 [TBL] [Abstract][Full Text] [Related]
5. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity. Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241 [TBL] [Abstract][Full Text] [Related]
6. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959 [TBL] [Abstract][Full Text] [Related]
7. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587 [TBL] [Abstract][Full Text] [Related]
8. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging. Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307 [TBL] [Abstract][Full Text] [Related]
9. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008 [TBL] [Abstract][Full Text] [Related]
10. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells. Li C; Guan X; Xue H; Wang P; Wang M; Gai X Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760 [TBL] [Abstract][Full Text] [Related]
11. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers. Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692 [TBL] [Abstract][Full Text] [Related]
12. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer. Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609 [TBL] [Abstract][Full Text] [Related]
13. Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance. Yu J; Chen H; Jiang L; Wang J; Dai J; Wang J J Pharm Sci; 2019 May; 108(5):1788-1799. PubMed ID: 30610857 [TBL] [Abstract][Full Text] [Related]
14. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793 [TBL] [Abstract][Full Text] [Related]
15. Chemosensitization of doxorubicin in multidrug-resistant cells by unimolecular micelles via increased cellular accumulation and apoptosis. Wang M; Han M; Li Y; Jin Y; Gao JQ J Pharm Pharmacol; 2016 Mar; 68(3):333-41. PubMed ID: 26893058 [TBL] [Abstract][Full Text] [Related]
16. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line. Shaik MS; Chatterjee A; Singh M J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869 [TBL] [Abstract][Full Text] [Related]
17. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. Li X; Jia X; Niu H Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236 [TBL] [Abstract][Full Text] [Related]
18. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers. Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866 [TBL] [Abstract][Full Text] [Related]
19. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles. Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072 [TBL] [Abstract][Full Text] [Related]
20. Near-infrared triggered co-delivery of doxorubicin and quercetin by using gold nanocages with tetradecanol to maximize anti-tumor effects on MCF-7/ADR cells. Zhang Z; Xu S; Wang Y; Yu Y; Li F; Zhu H; Shen Y; Huang S; Guo S J Colloid Interface Sci; 2018 Jan; 509():47-57. PubMed ID: 28881205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]